BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Watch SpaceX launch powerful ocean-mapping satellite for Europe and NASA early Nov. 17 - 2The World's Dazzling Regular Miracles
- 3Figure out how to Keep up with Your Dental Inserts for Long haul Achievement
- 4Top Frozen yogurt Flavor: Cast Your Vote!
- 5Fundamental Home Machines for Improved Solace in Summer
- Little Urban areas to Visit in Western Europe
- What we know about Renee Nicole Good, the woman who was killed by an ICE officer in Minneapolis
- Israel's ban on unsupervised reporters in Gaza causes strategic harm to legitimacy
- How to watch ‘The Traitors’ U.K. Season 4 premiere today from the U.S.
- Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom
- Extreme Manual for Purchasing Your Next Truck
- 21 Things You Ought to Never Share with Your Childless Companion
- Vote in favor of the Top Vegetable for Senior
- Explainer-What Novo Nordisk's weight-loss pill approval means for company, patients
